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Strengths and limitations of the study
 ► This is the first randomised placebo- controlled trial 
designed to study the effect of melatonin in reducing 
caesarean section rates.
 ► Both the participants and the clinicians providing 
care will be blinded to the trial intervention alloca-
tion, thus decisions regarding the need for a caesar-
ean section cannot be influenced by the allocation.
 ► A potential limitation of this study is that it is con-
ducted at a single health service.
AbStrACt
Introduction Induction of labour (IOL) is a common 
practice. In Australia, up to 40% of women undergoing 
labour induction will ultimately have a caesarean section. 
As a biological role for melatonin in the onset and progress 
of labour has been demonstrated, we aim to test the 
hypothesis that addition of melatonin will reduce the need 
for caesarean section.
Methods and analysis This is a double- blind, 
randomised, placebo- controlled trial in women undergoing 
IOL at term. We plan to randomise 722 women (1:1 ratio) 
to receive either melatonin (four doses of 10 mg melatonin: 
first dose—in the evening at the time of cervical balloon 
or Dinoprostone PGE
2 vaginal pessary insertion, second 
dose—at time of oxytocin infusion commencement, 
third dose—6 hours after the second dose, fourth 
dose—6 hours after the third dose) or placebo (same 
dosing regime). Participants who are having artificial 
rupture of the membranes only as the primary means of 
labour induction will receive up to three doses of the trial 
intervention. The primary outcome measure will be the 
requirement for a caesarean section. Secondary outcomes 
will include duration of each stage of labour and time from 
induction to birth, total dose of oxytocin administration, 
epidural rate, indication for caesarean section, rate of 
instrumental deliveries, birth within 24 hours of induction 
commencement, estimated blood loss, Apgar score 
at 5 min, neonatal intensive care unit admissions and 
participant satisfaction. Maternal melatonin levels will 
be measured immediately before commencement of the 
oxytocin intravenous infusion and 3 hours after and at the 
time of birth in order to determine any differences between 
the two trial arms.
Ethics and dissemination The study is conducted in 
accordance with the conditions of Monash Health HREC 
(RES-17-0000- 168A). Findings from the trial will be 
disseminated through peer- reviewed publications and 
conference presentations.
Protocol version V.7.0, 30 July 2019.
trial registration number ACTRN12616000311459, 
Universal trial number: (UTN) U1111-1195-3515.
IntroduCtIon
Induction of labour (IOL) is one of the most 
common obstetric interventions. In Australia, 
the labours of 33% of women are induced, 
up from 25% only a decade earlier.1 2 IOL 
is principally performed with the intent of 
reducing risks to the mother and/or baby 
by simply calling an end to the pregnancy. 
Ideally, the induced labour progresses to a 
vaginal birth. However, despite randomised 
controlled trials indicating that IOL does not 
increase caesarean section rates3 4 outside 
of the tight confines of trials, the reality for 
women in high- income nations is that up to 
~40% of women having their labours induced 
will require a caesarean section, this is partic-
ularly true if they are nulliparous.5–9
Failure of IOL resulting in a caesarean 
section is important for a number of reasons. 
First, it may be associated with disappointment 
for the woman. There are well- established 
links between the need for a caesarean birth 
and the risk of postnatal depression10 and 
post- traumatic stress disorder, particularly in 
first- time mothers.11 Women who require a 
caesarean section are also less likely to breast-
feed their baby.12 13 An intrapartum caesarean 
is associated with greater maternal morbidity 
than vaginal birth, including higher rates 
of postpartum haemorrhage, endometritis, 
venous thromboembolism, a longer recovery 
time and an increased rate of hospital read-
mission.14 15 Having a caesarean section is also 
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associated with an increased risk of morbidities in subse-
quent pregnancies including preterm birth, abnormal 
placentation and uterine rupture.16 17 Improving the 
success of IOL is therefore important not only for the 
current labour but also for all future pregnancies.
It is most common practice in Australia for the IOL 
process to begin in the morning. Optimum staffing levels 
are considered the main driver for this.18 However, such 
timing may not be optimal for the woman. First formally 
reported over 60 years ago was the observation that 
spontaneous labour most commonly starts at night.19 
In a study of 19 000 labours, the peak time of onset was 
between 02:00 and 03:00.19 More interestingly, labours 
commencing between 23:00 and 01:00 were significantly 
shorter than those that commenced between 04:00 and 
19:00.19 Over the years, these intriguing observations 
have been confirmed by others (reviewed in Serón- Ferré 
et al20). The accepted explanation underlying the obser-
vations has been that uterine muscle (myometrial) fibres 
are more sensitive to the effects of endogenous oxytocin 
at night.21 22 The reason for this increased sensitivity at 
night is thought to be due to melatonin.
Melatonin (5- methoxy- N- acetyltryptamine) is an 
endogenous hormone produced primarily by the pineal 
gland. It provides circadian and seasonal timing cues.23 In 
adults, melatonin levels remain low throughout the day. 
In the early evening, the levels begin to increase, peaking 
between 02:00 and 03:00 and then falling back down 
to low daylight concentrations again in the morning.24 
This circadian rhythm of melatonin is amplified in 
pregnancy. In particular, healthy pregnant women have 
higher concentrations of melatonin both at night and 
during the day compared with non- pregnant women25 
most likely due to de novo placental synthesis.26 In addi-
tion, maternal melatonin levels increase with advancing 
gestation peaking during labour and then falling 
rapidly after birth.26 The myometrium (uterine muscle) 
expresses the melatonin receptor MT2 and it is more 
highly expressed in labouring myometrium, collected 
at intrapartum caesarean section, than in myometrium 
from non- labouring women.27 The role of melatonin in 
the onset of active labour has not been widely studied; 
however, studies demonstrating increased myometrial 
expression of melatonin receptions among preterm birth 
suggest a role.26 Melatonin also increases the sensitivity 
of the myometrium to oxytocin- induced contractions.28 
Cotreatment of an immortalised myometrial cell line with 
melatonin and oxytocin resulted in a twofold increase in 
contractile response compared with oxytocin alone.28 In 
these same studies, melatonin was also shown to increase 
the expression of the protein connexin 43, a gap- junction 
protein necessary for myometrial cell communication 
and the synchronisation of uterine contractions.28 Taken 
together, these in vivo and in vitro observations suggest 
that melatonin plays a biological role in the timing of 
onset of spontaneous labour and in the effectiveness of 
spontaneous uterine contractions in labour. As IOL with 
an oxytocin intravenous infusion normally occurs during 
the daytime in the Australian setting, women do not 
experience the physiological increases in melatonin that 
occur prior to going into spontaneous labour at night, we 
hypothesise that administering melatonin at the time the 
induction process commences will reduce the IOL failure 
rate. We will undertake a double blind, randomised, 
placebo- controlled trial of oral melatonin administra-
tion at IOL to reduce caesarean section rates in healthy 
women with a singleton pregnancy at full term.
MEthodS And AnAlySIS
This protocol has been designed in accordance with the 
SPIRIT (Standard Protocol Items: Recommendations for 
Interventional Trials) 2013 Guidelines (see online supple-
mentary file 1, WHO Trial Registration Dataset).
Study design
This is a phase III double- blind, randomised, placebo- 
controlled trial.
trial timeline
The study is conducted on March 2019–March 2022.
Study setting
Participants will be recruited at Monash Health, Monash 
Medical Centre, a level six university affiliated teaching 
hospital in metropolitan Melbourne, which provides 
care for up to 9000 women a year. Approximately 10 
women who meet our inclusion and exclusion criteria are 
induced per week at this institution.
Subjects
Women with a singleton pregnancy who are undergoing 
IOL participated in the study.
Inclusion criteria
 ► ≥18 years and <50 years of age.
 ► Nulliparous or multiparous (para 1–3) women with a 
singleton pregnancy in cephalic presentation.
 ► Full term (≥37 weeks).
 ► Bishop’s score <5 (a strongest predictor of failure of 
induction).29
 ► Intact membranes.
 ► Method of induction includes the use of a cervical 
balloon catheter and/or Dinoprostone PGE2 (gel/
tablets/pessary) or women who are only having an 
amniotomy as the initial method of IOL.
 ► No known significant maternal or obstetric medical 
condition that would affect melatonin pharmacoki-
netics or maternal safety.
Specific exclusion criteria
 ► Fetal growth restriction <10th centile with Doppler 
changes.
 ► Any known congenital anomaly of the fetus.
 ► Any known abnormal karyotype of the fetus.
 ► Non- reassuring fetal status.
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 ► Not willing to or inability to follow the procedures 
outlined in participant information and consent form.
 ► Known allergy or sensitivity to melatonin and its 
formulation.
 ► Mentally or legally incapacitated or not able to provide 
informed consent.
 ► Participation in another trial where there is pharma-
ceutical or any other nutritional intervention.
Participant recruitment and informed consent
Potential participants are those who are booked for 
labour induction from across the hospital’s maternity 
departments. A researcher, not involved in the provision 
of clinical care, will approach all eligible women and 
provide the Participant Information and Consent Form 
(see online supplementary file 2). The researcher will 
then provide a verbal explanation of the trial, including a 
description of the trial processes, the voluntary nature of 
the trial and that a decision to participate, or not, will not 
affect their clinical care. The woman will be encouraged 
to discuss their participation with others of their choosing 
and given sufficient time to consider if they wish to take 
part, or not. If the woman agrees to participate, she will 
provide written informed consent.
randomisation and blinding
A perinatal epidemiologist with no involvement in the 
clinical trial will prepare the randomisation sequence 
that is given to an onsite dedicated clinical trial pharmacy. 
Randomisation will occur on a 1:1 ratio of melatonin to 
placebo. Both the melatonin and the placebo tablets will 
be indistinguishable and contained in individually pre- 
prepared bottles by the clinical trial pharmacist who is 
likewise not involved in participant recruitment of trial 
conduct. Neither the researcher, the clinical staff nor 
the participants will know whether melatonin or placebo 
tablets have been administered. At the time of recruit-
ment, each participant will be deidentified and assigned 
a unique trial code. Subsequently, all data and tissue 
samples collected from the participant will be labelled 
and stored only with this associated code.
Study intervention
Participants will be given either melatonin 10 mg 
(Circadin prolonged release melatonin, manufactured 
by Aspen Pharma, New South Wales, Australia) tablets or 
visually identical placebo tablets manufactured by a Good 
Manufacturing Practice (GMP)- compliant compounding 
pharmacy. The administration regimen of the trial inter-
vention will be determined by the method of labour 
induction.
Cervical balloon and/or Dinoprostone PGE2 (pessary/tablet/gel) 
(evening admission)
Participants who are having a cervical balloon and/or 
Dinoprostone PGE2 (pessary/tablet/gel) will receive up 
to four doses of the trial intervention: first dose—in the 
evening at the time of initial cervical balloon or Dinopro-
stone PGE2 vaginal pessary/gel/tablet insertion, second 
dose—at the time of the oxytocin intravenous infusion 
commencement, third dose—6 hours after the second 
dose and fourth dose—6 hours after the third dose.
Artificial rupture of membranes only (morning admission)
Participants who are having artificial rupture of the 
membranes (ARM) only as the primary means of labour 
induction will receive up to three doses of the trial inter-
vention: first dose—following the ARM procedure—at 
the time of the oxytocin infusion commencement, second 
dose—6 hours after the first dose and third dose—6 hours 
after the second dose.
For both of the trial intervention administration regi-
mens, if birth occurs before all of the doses have been 





1. Total length of labour (including the duration of 
first, second, third stages of labour).
2. Induction commencement to birth interval (time of 
start of induction (either with balloon or cervidil or 
ARM and oxytocin) to the time of delivery).
3. Total dose of oxytocin administered.
4. Estimated blood loss in millilitres (from birth to 
24 hours postpartum).
5. Instrumental vaginal birth (total and within 24 hours 
of IOL commencement).
6. Uterine tachysystole (more than five contractions in 
10 min without fetal heart rate changes).
7. Apgar score at 5 min.
8. Participant satisfaction with the labour assessed via a 
five- point Likert scale (How would rate your overall 
experience of your induction?)
9. Postnatal length of stay.
10. Admission of the baby to neonatal intensive care unit 
(ICU) (from birth to discharge of the baby) as per 
the decision of consultant neonatologist.
11. Participant melatonin levels will be determined prior 
to the administration of the second dose of the trial 
intervention and commencement of the oxytocin in-
travenous infusion, 3 hours after the administration 
of the second dose of the trial intention and within 
20 min of giving birth.
12. Umbilical cord blood melatonin levels (collected at 
the time of birth).
13. Economic impact: The total resources and costs will 
be compared from the time of admission to the dis-
charge of the participant and her baby. Economic 
outcome measures include personnel costs, medica-
tion and other clinical costs; this will be performed 
in compliance with the International Society for 
Pharmacoeconomics and Outcomes Research good 
practice standards.30
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Table 1 Detectable differences in secondary outcomes
Secondary outcomes
Mean (SD) or proportion in untreated 
group based on our health service data
Two- sided detectable difference based 
on primary outcome sample size
Length of first stage of labour (hours) 8.22 (5.66) −1.2 or 1.2 hours
Length of second stage of labour (min) 55 (65) −13.6 to 13.6 min
Length of third stage of labour (min) 6 (13.6) −2.8 to 2.8
Duration of oxytocin infusion (hours) 7.22 (4.46) −0.93 or 0.93 hours
Total volume of oxytocin administered 
(milliunits/min)
69.6 (43) −8.9 or 8.9 units
Blood loss (mL) 459.8 (328) −68.5 or 68.5 mL
Apgar score <7 at 5 min 2% 0.0% or 6.1%
Admission to NICU 1.3% 0.0% or 4.9%
Epidural use 31% 22% or 41%
NICU, neonatal intensive care unit.
Covariates/Confounders
Maternal age (years), maternal weight and height at time 
of induction, parity, maternal self- reported country of 
birth, Bishop score/cervical dilation at time of labour 
onset, pain relief in labour, time of birth and indication 
for operative birth, if relevant.
Sample and data collection
Participant blood samples are collected: (1) just prior to 
commencement of the intravenous oxytocin infusion and 
intervention (tablet) administration, (2) 3 hours after the 
oxytocin infusion has started and (3) at birth. Melatonin 
concentration will be measured using a commercial kit 
(RK- MEL2; Buhlmann Laboratories, Schonenbuch, Swit-
zerland). Prior to participant discharge from hospital, all 
data relevant to the outcomes (including safety outcomes) 
will be collected by accessing their hospital records. The 
participants will be visited in the postnatal ward by a 
member of the research team to ask for general feedback 
regarding their participation in the trial.
Confidentiality and data collection
Confidentiality of all the participants data will be strictly 
maintained by all the researchers and in line with the 
national and local guidelines. All members of the Data 
Safety Monitoring Board (DSMB) will be provided with 
deidentified data only (ie, bearing only the unique partic-
ipant code). All data collected from the participants will be 
gathered on a standardised case report form and entered 
onto a password- protected dedicated trial database. The 
original hard copy, case report form will be stored in a 
locked filling cabinet located in a secure, departmental 
location. After completion of the trial, all trial- related data 
and records will be retained for a minimum of 15 years 
in accordance with Monash Health and National Health 
Medical Research Council (NHMRC) requirements for 
clinical trials. After this period has been reached, all 
trial- related data and records will be deleted or undergo 
secure destruction.
Sample size
This trial has been powered to detect a 10% absolute 
reduction in the rate of the primary outcome: caesarean 
section. This was determined to reflect a clinically signifi-
cant decrease in caesarean section rate as per the healthy 
people 2020 targets,31 an initiative of the American 
Federal Government that recommends a 10% reduc-
tion in caesarean rates. The rate of caesarean section at 
term among primiparous women undergoing IOL at our 
health service from 2009 to 2015 is ~37%. Therefore, to 
detect a reduction in caesarean section rates from 37% 
to 27%, we will recruit a total of 722 women (361 in each 
arm). With a total of 722 women, the detectable differ-
ences in each of our secondary outcomes are detailed in 
table 1.
Statistical analysis
All analyses will be performed using intention- to- treat. All 
continuous data will be assessed for normality. Character-
istics of the two groups will be tabulated and compared 
using the appropriate statistical test (χ2, independent 
t- test, Mann- Whitney test). Differences in the primary 
outcome will be assessed by logistic regression adjusting 
for confounders/baseline imbalances between groups if 
appropriate. Differences in the secondary outcomes will 
be assessed using the appropriate regression method 
adjusting for confounders/baseline imbalances between 
groups if appropriate. Rates of the primary and secondary 
outcomes will also be reported by parity. The costs will 
be calculated separately for each mother/infant pair. A 
p value of <0.05 will be considered to indicate statistical 
significance. Analyses will be undertaken using StataCorp 
V.12 (StataCorp. 2011. Stata Statistical Software: Release 
12. College Station, Texas, USA: StataCorp LP.)
Adverse events
Adverse events and serious adverse events will be identi-
fied according to International Conference on Harmon-
isation Good Clinical Practice (ICH GCP) definitions. 
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The lead principal investigator (PI) who is an AHPRA 
registered medical doctor is responsible for all trial- 
related medical decisions; this includes the assessment 
unexpected events and, where necessary, attribution of 
causality to those which have been determined as adverse 
events.
To date, clinical studies have not demonstrated any 
serious adverse reactions to the use of melatonin. 
However, there may be unexpected reactions associated 
with melatonin when used at IOL in pregnant women 
that we do not yet know about. Therefore, participants 
and their babies will be assessed for any adverse events 
from the time of induction commencement until their 
discharge from hospital signifying their completion in 
the trial. All adverse events will be recorded and reported 
in accordance with the requirements of the Sponsor, 
Monash Health and NHMRC (National Health and 
Medical Research Council) guidance. The responsibility 
for the assessment, documentation and reporting of all 
such events is held by the PI.
For the purposes of this clinical trial, it is reasonable 
to remain mindful of the potential for side effects and 
adverse reactions. The accompanying literature and/or 
product information for melatonin shows that adverse 
effects are rare, that is, likely to occur in fewer than 1 
in 1000 persons which includes: Irritability, nervous-
ness, restlessness insomnia, abnormal dreams, anxiety, 
migraine, lethargy, psychomotor hyperactivity (rest-
lessness associated with increased activity), dizziness, 
somnolence (tiredness), high blood pressure, (upper) 
abdominal pain, indigestion, mouth ulceration, dry 
mouth, hyperbilirubinaemia (changes in the composi-
tion of your blood which could cause yellowing of the 
skin or eyes (jaundice), inflammation of the skin (derma-
titis, night sweats, pruritus (itching), rash, dry skin, 
pain in extremities, menopausal symptoms, asthenia 
(feeling of weakness), chest pain, excretion of glucose 
in urine, excess proteins in the urine, abnormal liver 
function and weight increase, shingles, reduced number 
of white blood cells in the blood, decreased number of 
platelets in the blood, high level of fatty molecules in 
the blood, severe chest pain due to angina, feeling your 
heartbeat (palpitations,. low serum calcium levels in the 
blood, low sodium levels in the blood, altered mood, 
aggression, agitation, crying, stress symptoms, disorien-
tation, early morning awakening, increased sex drive, 
depressed mood, depression, loss of consciousness or 
fainting, memory impairment, disturbance in attention, 
dreamy state, restless legs syndrome, poor quality sleep, 
‘pins and needles’ feeling (paraesthesia) reduced visual 
acuity (visual impairment), blurred vision, watery eyes, 
dizziness when standing or sitting, vertigo, hot flushes, 
gastro- oesophageal reflux, gastrointestinal disorder, blis-
tering in the mouth, tongue laceration, gastrointestinal 
upset, vomiting, abnormal bowel sounds, flatulence 
(wind), salivary hypersecretion (excess saliva produc-
tion), halitosis (bad breath), abdominal discomfort, 
gastric disorder, inflammation of the stomach lining, 
eczema, erythema (skin rash), hand dermatitis, psori-
asis, pruritic rash (itchy rash), nail disorder, arthritis, 
muscle spasms, neck pain, night cramps, tiredness, pain, 
thirst, passing large volumes or urine, presence of red 
blood cells in the urine, urination during the night, 
increased liver enzymes, abnormal blood electrolytes 
and abnormal laboratory tests.
data and safety monitoring board
As the use of melatonin is not indicated in current use in 
pregnancy for IOL, a DSMB was established. The DSMB 
comprises two Australian Health Professional Regula-
tory Agency (AHPRA) registered medical doctors, one a 
neonatologist and one obstetrician, as well as a biostatis-
tician. Data will be provided to DSMB in a deidentified 
form following the recruitment of 30% and 60% partic-
ipants, or at other times as requested by the DSMB or 
the Sponsor, Monash Health Research Directorate and 
Human Research Ethics Committee. No interim statis-
tical analysis of the primary or secondary outcomes is 
planned. The DSMB are advised to advocate complete 
cessation, or re- evaluation, of the trial conduct, if it is 
evident that either arm of the trial is associated with a 
statistically significant increase in or a 50% increased rate 
above the baseline ratio of any, or all, of the following 
outcome:
 ► Episodes of any or all of the following: uterine tachy-
systole (more than five contractions in 10 min without 
fetal heart rate changes), uterine hypertonus (defined 
as contractions lasting longer than 2 min in duration 
or occurring within 60 s of each other without fetal 
heart rate abnormalities) and uterine hyperstimu-
lation(tachysystole or uterine hypertonus with fetal 
heart rate abnormalities).
 ► Estimated blood loss ≥500 mL for vaginal birth or 
≥750 mL at caesarean birth.
 ► Participant entry to ICU, high dependency unit or 
coronary care unit.
 ► Uterine rupture.
 ► Apgar score <7 at 5 min of age requiring active resusci-
tation (this include oxygen therapy, intermittent posi-
tive pressure ventilation, endotracheal intubation, 
continuous positive airway pressure or laryngoscopy).
 ► Maternal or perinatal death.
trial modification and discontinuation
There will be no allowances to modify the trial intervention 
administration regimen or other trial- related processes. 
The participant maybe or discontinued from the trial for 
reasons including not able to follow the procedures, in 
violation with the protocol, adverse drug reaction to the 
trial tablets or at their own request. The PI will determine 
if more participants will be needed to increase the sample 
size to compensate for loss to follow- up/discontinua-
tion/withdrawal. The trial may also be discontinued at 
the request of the Human Research Ethics Committee/
Research Directorate or at the request of the DSMB.
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unblinding
Deliberate unblinding in the trial may occur in the 
following circumstances:
 ► To make clinical treatment decisions or when an 
unexpected serious adverse event occurs and the 
intervention must be made known.
 ► At the request of the DSMB.
 ► At the conclusion of the study to determine the effect 
of the intervention.
For individual unblinding, the lead clinical PI will assess 
and authorise the need for unblinding. The process 
for individual unblinding will involve the clinical PI 
contacting the site pharmacy and providing the partici-
pant identification number. On unblinding, the partici-
pant will be recorded as withdrawn from the trial.
Patient and public involvement
There has been no patient or public involvement in the 
trial design. All women will be asked about their satis-
faction with the IOL (secondary outcome measure) and 
feedback regarding their participation in the trial will 
also be sought.
Ethics and dissemination
The clinical trial will be carried out in accordance with 
the conditions of Monash Health Human Research Ethics 
Committee (HREC approval), National Health Medical 
Research Council (NHMRC) National Statement on 
Ethical Conduct in Human Research 2007 (updated 
2018) and the NHMRC Australian Code for the Respon-
sible Conduct of Research (2018).32 33 On completion of 
the trial, its findings will be presented at scientific meet-
ings and published in peer- reviewed journals.
dISCuSSIon
The rates of IOL are increasing globally. The ultimate aim 
of IOL, beyond a healthy mother and baby, is to achieve 
a vaginal delivery. However, for up to 37% women having 
their labour induced, this does not occur and they will 
require a caesarean section. The trial is the first double- 
blind, randomised, placebo- controlled trial of melatonin 
administration at IOL. If successful, it will show that this 
inexpensive and safe supplement will improve the rate of 
vaginal birth and reduce total healthcare costs. As such, 
this trial could be responsible for the first fundamentally 
new development in labour care for many decades
trial status
The trial commenced March 2019.
Protocol amendments
The PIs will be responsible for informing the sponsor, 
Monash Health, of any proposed protocol amendments, 
in accordance with local requirements.
dissemination policy
Following completion of the trial, it is intended that the 
aggregated results will be published in peer- reviewed 
journals and presented at scientific conferences. A 
summary of the trial findings will be provided to those 
participants who have requested to receive this.
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